William Blair Investment Management LLC Sells 11,828 Shares of ANI Pharmaceuticals, Inc. $ANIP

William Blair Investment Management LLC trimmed its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 4.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 246,345 shares of the specialty pharmaceutical company’s stock after selling 11,828 shares during the quarter. William Blair Investment Management LLC owned approximately 1.07% of ANI Pharmaceuticals worth $17,897,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in ANIP. KBC Group NV bought a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Versant Capital Management Inc boosted its holdings in shares of ANI Pharmaceuticals by 103.3% in the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 217 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $32,000. USA Financial Formulas bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, Sterling Capital Management LLC grew its position in ANI Pharmaceuticals by 850.0% during the 3rd quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company’s stock worth $50,000 after acquiring an additional 612 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $70.80, for a total transaction of $35,400.00. Following the completion of the sale, the vice president directly owned 72,924 shares of the company’s stock, valued at approximately $5,163,019.20. The trade was a 0.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeanne Thoma sold 1,000 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $71.53, for a total value of $71,530.00. Following the sale, the director directly owned 26,762 shares of the company’s stock, valued at $1,914,285.86. This represents a 3.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 27,250 shares of company stock worth $1,975,156 in the last ninety days. 8.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $71.44 on Monday. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 2.30 and a beta of 0.45. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.33 and a current ratio of 2.75. The business’s fifty day moving average price is $72.32 and its two-hundred day moving average price is $77.00. ANI Pharmaceuticals, Inc. has a 52 week low of $67.14 and a 52 week high of $87.76.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last released its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.18 by $0.52. ANI Pharmaceuticals had a return on equity of 28.34% and a net margin of 11.22%. The company had revenue of $290.78 million during the quarter, compared to the consensus estimate of $280.59 million. During the same quarter in the previous year, the company posted $2.04 earnings per share. The firm’s quarterly revenue was up 27.6% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Wednesday, November 4th. Oppenheimer initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price objective on the stock. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective on the stock. Guggenheim increased their target price on ANI Pharmaceuticals from $119.00 to $121.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Finally, Canaccord Genuity Group lowered their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $100.00.

Get Our Latest Stock Analysis on ANI Pharmaceuticals

ANI Pharmaceuticals Profile

(Free Report)

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.

See Also

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.